 |
|
|
|
 |
|
|
| Article 1 to 10 out of 49 concerning Biovitrum AB
|
-
Merger of Biovitrum and Swedish Orphan
(26 Jan 2010)
Biovitrum and Swedish Orphan have combined forming Swedish Orphan Biovitrum. The mission of the new company is to develop and make available orphan drugs and niche specialty pharmaceuticals for patients with rare diseases and with high unmet medical ...
-
Biovitrum Sells Obesity Program to AstraZeneca
(23 Dec 2009)
Biovitrum AB announced that AstraZeneca has acquired all of Biovitrum’s rights to its leptin modulator program aimed at treating obesity. Biovitrum will receive from AstraZeneca an upfront payment of Euro 6M and milestone payments contingent on ...
-
Biovitrum Advances Novel Factor VIII Long-Acting Hemophilia A Therapy into Clinical Trials
(17 Dec 2009)
Biovitrum AB announced that the first patient was dosed in a phase I/IIa study of its long-acting fully-recombinant Factor VIII Fc fusion (rFVIIIFc) protein. The phase I/IIa open-label study will assess the safety, tolerability and pharmacokinetics ...
-
Kiobrina shows positive phase II results in preterm infants
(27 Nov 2009)
Biovitrum AB announced that the first of two clinical phase II studies, designed to together show proof of concept of Kiobrina(TM) (rhBSSL) in preterm infants, has been completed. The results show statistically significant improvement in the growth ...
-
Biovitrum Completes Divestiture of Cambridge Biotechnology
(25 Nov 2009)
Biovitrum AB announced that it has completed the divestiture of its wholly-owned subsidiary Cambridge Biotechnology Ltd (CBT), and the sale of certain drug development programs, to Proximagen Neuroscience plc. The drug development programs consist ...
-
Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial
(21 Oct 2009)
Biogen Idec and Biovitrum AB announced that they plan to advance the companies' long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients. The decision to advance the program ...
-
Biovitrum Transfers Two Metabolic Disease Projects to iNovacia
(24 Jun 2009)
Biovitrum AB and iNovacia AB announced an agreement to transfer the preclinical GPR 119 and SCD-1 projects from Biovitrum to iNovacia. The agreement includes a split of all future revenues from the projects 70:30 (iNovacia:Biovitrum). Biovitrum will ...
-
Biovitrum enters agreement with Karolinska Development
(19 Mar 2009)
Leukemia project to be pursued in a jointly owned project company
Biovitrum AB and Karolinska Development signed an agreement to establish a jointly owned project company. This company will receive all rights to further develop, market and sell Biovitrum's pharmaceutical project FLT3 against leukemia.Karolinska ...
-
Biovitrum aims to spin-out Cambridge Biotechnology
(26 Jan 2009)
Biovitrum AB announced the initiation of a process aiming to spin out its small molecule UK based R&D subsidiary Cambridge Biotechnology (CBT) and a range of primary care projects. The proposed transaction reflects Biovitrum's previously announced ...
-
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
(27 Nov 2008)
Biovitrum AB and Syntonix Pharmaceuticals, Inc., a subsidiary of Biogen Idec announced that the company's FIXFc compound for the control and prevention of hemorrhagic episodes in patients with hemophilia B has received an orphan-drug designation ...
Additional information
Biovitrum AB
Stockholm, Sweden
Company
|
|
|
|
|
|
Top
